Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | CDC25C | P30307 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133807 | 0.79 | IDO1 (0.50) | MAOBGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15594478 | 0.78 | CYP11B2 (0.44) | CASP1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL256008 | 0.77 | HSD11B1 (0.48) | CASP1MAOBGAANOTUMKDM1A | |
| SCHEMBL6676853 | 0.77 | GAA (0.50) | CASP1MAOBGABRA1GABRG2GABRB3 | |
| SCHEMBL15594490 | 0.75 | EGLN2 (0.38) | CYP11B2NPC1RAB9A | |
| SCHEMBL21578425 | 0.75 | GAA (0.41) | CASP1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL12824474 | 0.74 | LMNA (0.44) | CASP1MAOBGABRA1GABRG2GABRB3 | |
| SCHEMBL14872146 | 0.74 | KDM4E (0.56) | MAOBGAAGSK3BNPC1RAB9A | |
| SCHEMBL2314305 | 0.74 | MAPT (0.45) | MAOBHSD11B1NPC1RAB9A | |
| SCHEMBL3152568 | 0.74 | KDM4E (0.42) | GAAHSD11B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-5418233-A | FOR INHIBITING CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1995-05-23 | — | — | US | disclosed |
| EP-0608858-A1 | 5-Membered heterocycles as aggregation inhibitors | Dr. Karl Thomae GmbH (DE) | 1994-08-03 | — | — | EP | disclosed |
| US-5276049-A | Treatment of thrombosis | DR. KARL THOMAE GMBH (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0537696-A1 | Heterobiaryl derivatives, medicines containing those compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0528369-A2 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-02-24 | — | — | EP | disclosed |
| EP-0525629-A2 | 5-membered heterocycles, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1993-02-03 | — | — | EP | disclosed |
| EP-0503548-A1 | Cyclic urea derivatives, medicaments contaning them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-16 | — | — | EP | disclosed |
| US-4117130-A | 6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES | AMERICAN CYANAMID COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4092311-A | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates | AMERICAN CYANAMID COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | CASP1 1061/4885MAOB 406/4885GABRA1 2/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CASP1 1061/4885MAOB 406/4885GABRA1 2/4885 |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CASP1 1061/4885MAOB 406/4885GABRA1 2/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CASP1 1061/4885MAOB 406/4885GABRA1 2/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CASP1 2090/4885MAOB 1858/4885GABRA1 2263/4885 |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CASP1 1061/4885MAOB 406/4885GABRA1 2/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | CASP1 3830/4885MAOB 4036/4885GABRA1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.